Janssen Research & Development, Llc

This early-stage trial is testing a new drug called JNJ-79635322 in combination with other myeloma treatments (daratumumab, lenalidomide, or pomalidomide) in 140 people with multiple myeloma. The main goal is to find a safe and effective dose and to see how well the body tolerate…

This early-phase study is testing an experimental drug called JNJ-89402638 in people with metastatic colorectal or gastric cancer that has progressed after at least two prior treatments. The trial will first find the safest dose and schedule, then test the drug alone or combined …

This study is checking the long-term safety of guselkumab, a biologic drug given as a shot, in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a prior guselkumab study and benefited from i…

This study watches 200 adults with moderate-to-severe plaque psoriasis who have never taken a biologic before. They are starting treatment with guselkumab, and researchers will track how many continue the drug for two years. The goal is to see how well people stick with this trea…

This study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…

This phase 3 trial tests whether the experimental drug JNJ-78934804 can help people with moderate to severe ulcerative colitis achieve remission better than the existing drug guselkumab. About 644 participants will receive either the new drug or guselkumab, and researchers will c…

This study tests a new medicine, JNJ-78934804, against an existing drug (guselkumab) in 460 people with moderate-to-severe Crohn's disease. The goal is to see if the new drug can reduce symptoms and heal the gut lining better at 48 weeks. Participants must have had Crohn's for at…

This phase 2 study is testing whether adjusting the dose of ibrutinib—either by starting lower or reducing it when side effects occur—can still effectively control chronic lymphocytic leukemia (CLL) in people who have not yet been treated. Some participants will receive ibrutinib…

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which reduces harmf…

This early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dos…

This study is testing a drug called amivantamab, either alone or with standard chemotherapy, in people with advanced or metastatic colorectal cancer. The goal is to see if the combination can shrink tumors and to find the safest dose. About 225 participants will take part across …

This early-stage study tests a new drug called JNJ-88549968, a bispecific antibody designed to direct the body's immune T cells to attack cancer cells with a specific CALR mutation. The trial will enroll about 220 adults with essential thrombocythemia or myelofibrosis who carry t…

This study tests two new drug combinations (Tec-DR and Tal-DR) against a standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if the new combos keep the cancer from growing longer and help more patients ach…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…

This study tests an oral medication called icotrokinra for people with moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the colon. About 882 adults and adolescents will receive either the drug or a placebo to see if it can bring ab…

This study tests whether guselkumab works better than risankizumab for people with moderate to severe Crohn's disease. About 530 adults will receive one of the two drugs and be followed for a year. The goal is to see which drug leads to deeper remission, meaning fewer symptoms an…

This early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combin…

This phase 3 study compares a new injectable drug, JNJ-79635322, to an existing one, teclistamab, in about 700 people with multiple myeloma that has returned after 1 to 3 prior treatments. The goal is to see which drug works better at shrinking tumors and delaying disease progres…

This study tests a new drug called talquetamab in people with multiple myeloma that has come back or stopped responding to treatment. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to find the best dose and see how well…

This early-stage trial is testing a new drug called JNJ-95566692, a trispecific antibody designed to target lymphoma cells. It is given alone or with another drug (JNJ-87801493) to about 130 people whose B-cell non-Hodgkin lymphoma has not responded to or returned after at least …

This Phase 3 trial tests whether adding pasritamig, a drug that directs the body's T-cells to attack prostate cancer cells, to standard chemotherapy (docetaxel) can slow cancer growth better than chemotherapy alone. The study involves 800 men with metastatic castration-resistant …

This study tests a drug called bedaquiline in children and teens (0 months to under 18 years) with multidrug-resistant tuberculosis (MDR-TB), a lung infection that does not respond to standard antibiotics. About 60 participants will receive bedaquiline along with other TB medicat…

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutant NSCLC) that has spread. The goal is to find the safest and most effective dose and see if the combo can shrink tumors or slow their gr…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier studies for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The goal is to check long-term safety, including side effects and eye …

This study tests an experimental drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo to see if it improves skin symptoms by at least 75% after 12 weeks. The goal is to control the diseas…

This study compares a new drug delivery system (TAR-210) that releases erdafitinib directly into the bladder versus standard chemotherapy for people with intermediate-risk non-muscle invasive bladder cancer that has certain genetic changes (FGFR alterations). About 641 participan…

This study is tracking 150 people with early-stage bladder cancer who are receiving TAR-200, a treatment placed directly into the bladder. Researchers want to see how long it takes for the cancer to come back or get worse in real-world settings, not just in controlled trials. The…

This early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors whe…

This study provides ongoing access to daratumumab-based treatment for 500 adults with multiple myeloma who are already benefiting from it in earlier Janssen trials. The main goal is to monitor long-term safety, including serious side effects and infections. Participants continue …

This phase 3 study compares two new drug combinations (talquetamab plus pomalidomide or talquetamab plus teclistamab) against standard treatments for multiple myeloma, a blood cancer. About 795 participants will be randomly assigned to one of the groups. The goal is to see which …

This study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…

This study follows 295 multiple myeloma patients who previously received cilta-cel (a CAR-T cell therapy) to track long-term side effects. No new treatment is given. Researchers will monitor for new cancers, nerve disorders, autoimmune issues, and infections over time. The goal i…

This Phase 3 trial is testing whether adding the targeted drug amivantamab to standard immunotherapy and chemotherapy can help people with advanced head and neck cancer live longer. About 500 participants who have not had prior treatment for their recurrent or metastatic cancer w…

This study tests whether the experimental drug icotrokinra can reduce symptoms and gut inflammation in people with moderate-to-severe Crohn's disease. About 1,092 adults will receive either the drug or a placebo for up to 40 weeks. The goal is to see if the drug can bring about r…

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The first drug helps the immune system attack cancer cells, and the second aims to make the immune system work bet…

This study tests whether a drug called nipocalimab can prevent severe bleeding in unborn babies at risk of FNAIT, a condition where the mother's immune system attacks the baby's platelets. About 50 pregnant women with a history of FNAIT will receive either nipocalimab or standard…

This early-stage trial tests whether the experimental drug aticaprant is safe and tolerable when added to standard antipsychotic treatment for schizophrenia. About 64 clinically stable outpatients will receive either aticaprant or a placebo. The main goals are to see if the study…

This early-phase study is testing a new drug called pasritamig (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose. About 300 participants will be …

This study tests a new drug, JNJ-79635322, against another antibody treatment in people with multiple myeloma that has come back or stopped responding after at least three prior treatments. About 400 participants will be randomly assigned to one of the two treatments. The goal is…

This phase 3 trial tests a new drug, TAR-210 (erdafitinib), placed directly into the bladder, against standard chemotherapy for people with a high-risk type of bladder cancer that has come back after BCG treatment. The study includes 220 adults whose tumors have certain FGFR gene…

This phase 3 study tests a drug called pasritamig, which helps the body's immune T-cells attack prostate cancer cells. The trial includes 663 men with metastatic castration-resistant prostate cancer, a stage where standard hormone therapy no longer works. Participants receive eit…

This early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger…

This study tests whether the experimental drug JNJ-88545223 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. About 240 participants will receive either the drug or a placebo to see if it works better than no treatment. The goal is to i…

This study is looking at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Researchers will follow 60 patients who are already scheduled to receive this treatment to see …

This phase 2 trial is testing amivantamab, a targeted cancer drug, given as a simple shot under the skin (instead of an IV drip) in people with advanced non-small cell lung cancer that has specific EGFR mutations. The study will enroll about 520 participants across several groups…

This study tests an experimental drug called JNJ-79635322 in people with multiple myeloma that has returned or stopped responding after at least 3 prior treatments. The goal is to see how well the drug shrinks or controls the cancer. About 157 participants will receive the drug a…

This phase 3 trial is testing whether a new drug called amivantamab, combined with standard chemotherapy (FOLFIRI), can help people with advanced colorectal cancer live longer without their disease getting worse. The study includes 700 participants whose cancer has returned or sp…

This study tests a medicine called nipocalimab to see if it can lower the risk of severe bleeding or death in unborn babies with a rare condition called FNAIT. The study includes 39 pregnant women who have had a previous pregnancy affected by FNAIT. Participants receive either ni…

This study tests a drug called amivantamab, either alone or combined with other cancer drugs (pembrolizumab, paclitaxel, carboplatin), in people with head and neck cancer that has spread or come back. The goal is to see if these treatments are safe and can shrink tumors. About 28…

This early-phase study tests two experimental drugs (JNJ-87189401 and JNJ-78278343) that help the immune system attack prostate cancer cells. The study involves about 355 men with advanced prostate cancer. The main goal is to find the safest dose and check for side effects.

This early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in people with relapsed or refractory multiple myeloma or AL amyloidosis. About 180 participants will receive the drug to find a safe dose and check for s…

This study compares two drug combinations for people with advanced left-sided colorectal cancer that cannot be removed by surgery. Participants receive either amivantamab or cetuximab along with chemotherapy. The goal is to see which combination helps keep the cancer from growing…

This study is testing how well the drug guselkumab works for people with psoriatic arthritis, a condition that causes joint pain and skin patches. Researchers will use ultrasound to measure joint inflammation in 200 participants over 24 weeks. The goal is to see if guselkumab red…

This study tests a new cancer treatment called cilta-cel for people with multiple myeloma, a type of blood cancer. The goal is to see if a modified chemotherapy preparation can make the treatment work better and be safer. About 60 participants will receive the therapy and be moni…

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About …

This phase 3 trial tests whether the drug nipocalimab can reduce the risk of severe anemia in unborn babies whose mothers have a condition called hemolytic disease of the fetus and newborn (HDFN). The study enrolls 120 pregnant women with a history of severe HDFN. Participants re…

This study tests a drug called erdafitinib, placed directly into the bladder using a special delivery system, for people with non-muscle-invasive or muscle-invasive bladder cancer. The trial has four parts to find the best dose and check safety and effectiveness. About 235 partic…

This study tests a new treatment for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). Participants receive either a combination of two drugs (amivantamab and lazertinib) as their first treatment, or amivantamab with chemotherapy if …

This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…

This early-stage trial is testing an experimental drug called JNJ-90189892 in about 155 people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have come back or not responded to treatment. The study has several parts: first, finding a safe dose of JNJ-90…

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining over 52 weeks. Participants must have active Crohn's confirmed by endoscopy. This is a phase 3 trial, meaning it…

This phase 3 study tests whether nipocalimab can help control moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 600 adults will receive either nipocalimab or a placebo, on top of standard treatments. The main goal is to see if more people …

This study tests whether the drug nipocalimab can delay or prevent relapses in adults with CIDP, a rare nerve disorder that causes weakness and numbness. Participants first receive nipocalimab, and those who improve are then randomly assigned to continue the drug or switch to a p…

This study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug reduces joint pain and skin symptoms better than a …

This study tests a drug called nipocalimab in children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely lowers certain immune proteins (IgG) and improves daily activities. About 12 children will receiv…

This study tests an investigational drug, nipocalimab, in adults with generalized myasthenia gravis (gMG), a condition causing muscle weakness. About 199 participants will receive either nipocalimab or a placebo to see if it improves daily activities and muscle strength. The drug…

This Phase 3 trial tests whether adding seltorexant (a drug that targets sleep) to standard antidepressants can improve mood and sleep in adults with major depression and insomnia who haven't fully responded to their current antidepressant. About 752 participants will receive eit…

This study tests whether certain mouth rinses or oral medications can prevent or reduce taste changes caused by the drug talquetamab, used to treat multiple myeloma. About 210 participants will be randomly assigned to different preventive treatments. The goal is to find a way to …

This study tests a new drug called seltorexant for people with major depression who also have trouble sleeping. About 600 adults will receive either the drug or a placebo to see if it improves mood and sleep. The goal is to find a new treatment option that targets both depression…

This study tests whether a nasal spray containing esketamine, given alongside standard care, can rapidly reduce symptoms of major depression and suicidal thoughts in adolescents. About 258 teens with acute suicidal ideation or behavior will receive either esketamine or a psychoac…

This study is a global registry that will follow 175 pregnant people whose babies are at risk for hemolytic disease of the fetus and newborn (HDFN), a condition where the mother's and baby's blood types clash, causing rapid red blood cell breakdown. Researchers will track how oft…

This early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…

This study is observing 380 people with a common type of advanced lung cancer caused by EGFR mutations who are receiving amivantamab as part of their routine care. Researchers will track how long patients stay on treatment and how well it controls the cancer in everyday medical p…